EMA Recommends Granting a Marketing Authorisation for Poherdy By Ogkologos - April 10, 2026 137 0 Facebook Twitter Google+ Pinterest WhatsApp It is a biosimilar of pertuzumab which was authorised in the EU in 2013 Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Disguising Cancer as an Infection Helps the Immune System Eliminate Tumors July 22, 2022 Chris Pratt Partners with GreaterGood to Support Food Banks and Feed... December 18, 2020 TAT 2021 Honorary Award: A Recognition in Cancer Drug Development to... February 16, 2021 Spotlight On: Occupational Therapists in Cancer Care November 4, 2021 Load more HOT NEWS ΚΑΡΚΙΝΟΣ ΘΥΜΟΥ ΑΔΕΝΑ (ΘΥΜΩΜΑ) The National Parks Service Still Hasn’t Fixed It’s Sexual Harassment Problem Can we grow the treatments of tomorrow? – That Cancer Conversation How to Cope With and Discuss an Uncertain Cancer Prognosis: An...
